XTX Topco Ltd Purchases New Position in Cardlytics, Inc. (NASDAQ:CDLX)

XTX Topco Ltd acquired a new position in shares of Cardlytics, Inc. (NASDAQ:CDLX) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 12,978 shares of the company’s stock, valued at approximately $107,000.

Several other institutional investors and hedge funds also recently modified their holdings of CDLX. Canton Hathaway LLC raised its holdings in shares of Cardlytics by 95.7% during the 2nd quarter. Canton Hathaway LLC now owns 4,500 shares of the company’s stock valued at $37,000 after buying an additional 2,200 shares during the period. Banco Santander S.A. acquired a new position in shares of Cardlytics during the first quarter worth $199,000. Quest Partners LLC boosted its stake in shares of Cardlytics by 160.4% in the second quarter. Quest Partners LLC now owns 17,956 shares of the company’s stock valued at $147,000 after purchasing an additional 11,061 shares during the period. Clear Street Markets LLC purchased a new position in shares of Cardlytics in the fourth quarter valued at $199,000. Finally, Virtu Financial LLC purchased a new stake in Cardlytics during the 4th quarter worth $219,000. Hedge funds and other institutional investors own 68.10% of the company’s stock.

Cardlytics Stock Performance

CDLX stock opened at $3.11 on Wednesday. The stock’s 50 day simple moving average is $4.68 and its 200 day simple moving average is $8.67. Cardlytics, Inc. has a 12-month low of $2.89 and a 12-month high of $20.52. The firm has a market cap of $151.72 million, a P/E ratio of -0.70 and a beta of 1.68. The company has a current ratio of 1.77, a quick ratio of 1.77 and a debt-to-equity ratio of 1.01.

Cardlytics (NASDAQ:CDLX) last issued its earnings results on Wednesday, August 7th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.12. Cardlytics had a negative net margin of 50.21% and a negative return on equity of 17.96%. The company had revenue of $69.64 million for the quarter, compared to analysts’ expectations of $75.39 million. During the same period in the prior year, the company earned ($0.57) earnings per share. The firm’s revenue was down 9.2% compared to the same quarter last year. As a group, equities research analysts predict that Cardlytics, Inc. will post -1.72 EPS for the current year.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Northland Capmk downgraded Cardlytics from a “strong-buy” rating to a “hold” rating in a research note on Friday, August 16th. Bank of America downgraded Cardlytics from a “neutral” rating to an “underperform” rating and dropped their price objective for the stock from $4.00 to $3.50 in a report on Thursday, August 15th. Craig Hallum cut Cardlytics from a “buy” rating to a “hold” rating in a research note on Thursday, August 8th. Needham & Company LLC lowered shares of Cardlytics from a “buy” rating to a “hold” rating in a research note on Thursday, August 8th. Finally, Lake Street Capital downgraded shares of Cardlytics from a “buy” rating to a “hold” rating and reduced their price objective for the company from $18.00 to $5.00 in a research note on Thursday, August 8th. One equities research analyst has rated the stock with a sell rating and five have issued a hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $7.50.

Insiders Place Their Bets

In related news, Director Scott A. Hill purchased 40,000 shares of the company’s stock in a transaction dated Monday, August 12th. The shares were acquired at an average cost of $3.58 per share, for a total transaction of $143,200.00. Following the transaction, the director now owns 40,000 shares of the company’s stock, valued at $143,200. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Cardlytics news, COO Amit Gupta sold 22,699 shares of the firm’s stock in a transaction that occurred on Wednesday, July 24th. The shares were sold at an average price of $8.66, for a total value of $196,573.34. Following the sale, the chief operating officer now owns 150,569 shares in the company, valued at $1,303,927.54. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Scott A. Hill purchased 40,000 shares of the business’s stock in a transaction dated Monday, August 12th. The shares were acquired at an average cost of $3.58 per share, for a total transaction of $143,200.00. Following the acquisition, the director now owns 40,000 shares of the company’s stock, valued at approximately $143,200. The disclosure for this purchase can be found here. 4.40% of the stock is currently owned by corporate insiders.

About Cardlytics

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.